Crocus offers scientists hope in the battle against cancer
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Monday 12 September 2011
A substance found in a native British flower has been turned into a powerful "smart bomb" drug that can work against a range of cancers.
The drug, based on colchicine found in the autumn crocus, cuts off the blood supply to solid tumours, curbing their growth and stopping cancer cells from spreading to other parts of the body.
Tests on laboratory mice have shown that the drug is highly effective at attacking tumours from a range of human diseases such as sarcomas and cancers of the breast, colon, lung and prostate. The drug is also designed to target solid tumours directly, leaving healthy tissue unaffected, according to Professor Laurance Patterson, director of Bradford University's Institute for Cancer Therapeutics.
"What we've designed is, effectively, a 'smart bomb' that can be targeted directly at any solid tumour to kill it without appearing to harm healthy tissue," Professor Patterson said.
"What is also new about our approach is that we are effectively targeting the blood supply of the tumour," he said. "If you can starve the tumour of that blood supply, then you can shut off its ability to grow and, indeed, you also shut off its ability to move around the body."
The drug is well known as having anti-cancer properties, but is normally toxic to healthy cells and so has had limited potential in medicine.
The trick used by the Bradford scientists is to attach colchicine to another molecule that renders the drug inactive until it comes into contact with a one of a class of enzymes called matrix metalloproteinases (MMPs), which are used uniquely by tumours to burrow into the body's healthy tissue, said Kevin Adams of the Bradford institute.
"The drug is inactive until triggered by the activity of an enzyme that is always found in the tumour environment but not elsewhere. Triggering releases a potent, anti-cancer agent which destroys the tumour's blood vessels, effectively starving the tumours to death, a process known as haemorrhagic necrosis," Dr Adams said. Tests on specially bred mice that have human cancerous tumours have shown that the drug and its delivery system can have a "cure rate" of greater than 70 per cent after a single dose, he said. Four different cancers have been treated and the animals suffered no adverse effects.
The next stage is a phase 1 clinical trial to test its initial safety, which is hoped to be conducted within 18 months at St James's University Hospital in Leeds.
- 1 End of the licence fee: BBC to back radical overhaul of how it is funded
- 2 This restaurant has misunderstood the concept of 'cheese and biscuits'
- 3 Raif Badawi, the Saudi Arabian blogger sentenced to 1,000 lashes, may now face death penalty
- 4 Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
- 5 PornHub turns masturbation into energy in bid to save the planet
New theory could prove how life began and disprove God
This is what it's like to be dead, according to a guy who died for a bit
End of the licence fee: BBC to back radical overhaul of how it is funded
'Jihadi John': CAGE representative storms off Sky News accusing Kay Burley of Islamophobia
Ukip would cut billions from Scottish budget to fund English tax cuts
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
£7 - £9 per hour: Recruitment Genius: Are you outgoing? Do you want to work in...
£45000 - £55000 per annum + 30 days holiday: Ashdown Group: Finance Manager - ...
£28000 - £30000 per annum: Ashdown Group: 3rd Line Support Engineer / Network ...
£26000 - £33000 per annum: Recruitment Genius: A Web Developer is required to ...